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Abstract We have cloned P2X4, a member of the P2-purinocep- 
tor family, which has a new pharmacological profile. Rat P2X 4 
is distantly related to P2XI, P2X2 and P2X 3 and is expressed in 
brain, spinal cord, lung, thymus, bladder, adrenal, testis and vas 
deferens. This ligand gated ion channel is activated by ATP and 
analogs with the potency order ofATP > ATP3,S > 2-methylthio 
ATP > ADP = ai~-methylene ATP. However, none of the cur- 
rently used P2X purinoceptor antagonists uramin, reactive blue 
2 and PPADS blocked ATP evoked currents; in contrast their 
application resulted in potentiation of the agonist response. Due 
to lack of any known antagonist for P2X 4 it is unlikely that native 
P2X 4 has previously been recognized as a P2X purinoceptor. 
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1. Introduction 
ATP is a widespread neurotransmitter [1]. Following the 
classification of P1- (adenosine as the endogenous ligand) and 
P2-purinoceptors (ATP and ADP as the endogenous ligands) 
for extracellular adenine nucleotides [2], many subtypes of P2- 
purinoceptors have been identified based on a large amount of 
pharmacological, electrophysiological and molecular biological 
studies [3]. Lately these receptors have been reclassified into 
P2X (ligand-gated) and P2Y (G-protein coupled) purinoceptor 
families [4,5]. Whereas P2Y receptors have the bonafide struc- 
ture of G-protein coupled receptors [6,7], recent cloning of 
P2X-purinoceptors identified them as a new family of ligand 
gated ion channels that is related to the inward rectifiers of 
potassium channels [8]. The three known P2X cDNAs are only 
about 35% identical to each other and have a somewhat narrow 
pattern of expression: P2Xj [9] shows a high level expression 
in vas deferens and a low expression in other tissues, P2Xz [10] 
has been found in PC12 cells and at lower levels in other tissues 
and the expression of P2X3 [11] is limited to dorsal root ganglia. 
ATP and 2-methylthio ATP (2-MeSATP) are the most po- 
tent agonists for recombinant P2Xz_3 purinoceptors. Suramin, 
reactive blue 2 (RB-2) and PPADS (pyridoxalphosphate-6-azo- 
phenyl-2',4'-disulphonic acid) are all efficient antagonists for 
those receptors that where tested [9,10,11]. 
ATP mediated responses in the CNS have been identified in 
the spinal cord [12]. More recently Edwards et al. [13] described 
fast synaptic transmission by ATP in the medial habenula sug- 
gestive of a role for ATP gated ion channels of the P2X type 
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(reviewed by [14]). Autoradiographic localization of [3H]~,fl- 
methylene ATP binding sites also indicates the presence of 
P2X-purinoceptors in the brain and spinal cord [15]. 
In this paper we describe the isolation of P2X4, a new P2X 
cDNA from rat brain. P2X 4 was found to be widely expressed. 
Recombinant P2X 4 purinoceptors are not blocked by currently 
used ATP purinoceptor antagonists and therefore define a new 
pharmacological type of P2X purinoceptors. 
2. Materials and methods 
2.1. Isolation of cDNA clone 
Standard DNA techniques were used [16]. A hippocampal cDNA 
library was screened with 32P-labeled probes derived from the P2X~ [9] 
and P2X2 [10] cDNA clones. The probes covered coding sequences 
only. Hybridization stringency was controlled by 20% formamide at 
42°C. Low stringency washing was controlled by the final wash in 1 × 
SSPE at 45°C. Positive clones were sequenced in both directions with 
ABI's (Applied Biosystems) cycle sequencing kit and ABI 373 se- 
quencer. 
2.2. Northern blot analysis 
Poly(A) ÷ rnRNAs were isolated using the Fast-Track II kit from 
Invitrogen (San Diego, USA) from fresh tissues of male Sprague 
Dawley rats (250 g). Nominally 3.2 ,ug of poly(A) ÷ mRNAs was size- 
separated through a formaldehyde-containing 1% agarose gel and 
transferred onto nylon membranes (Hybond N, Amersham Intl., Amer- 
sham, UK). A 600 bp fragment (30nt 5'UT segment through codon of 
aa 195) and 370 bp PCR derived fragment (codon for aa 354 through 
stop codon +270nt 3'UT segment) were used as 32p-labeled probes at 
high stringency. Hybridization was in 50% formamide at 42°C, and 
final wash was at 0.3× SSPE at 65°C. Both probes gave identical 
patterns of signals. Some blots were further washed at 0.1 x SSPE which 
did not change the pattern of detected signals. 
2.3. In situ hybridization 
Freshly obtained brain and spinal cord were cut to 14 ¢tm thick 
sections on a cryostat. Sections were thaw-mounted onto silanized glass 
slides and fixed immediately in 4% paraformaldehyde following the 
protocol of refs. [17,18]. Prehybridization i  50% formamide, 37°C for 
3 h, followed by overnight hybridization at 55°C, 50% formamide. 
Final wash was in 0.1 × SSC, 50% formamide, 55°C 3 × 30 rain. Same 
DNA segments as in Northern blots were used as probes. However, for 
in situ hybridization, digoxigenin labeled RNA probes (Dig-probes) 
were used. These Dig-probes were obtained as run-off transcripts on 
linearized plasmid DNA following manufacturer's instructions (Dig 
RNA labeling kit, Boehringer Mannheim). Hybridization was revealed 
through anti-Dig-alkaline phosphatase antibodies and visualized as 
dark brown color (DigNucleic acid detection kit, Boehringer 
Mannheim) followed by microphotography. Four repetition of in situ 
hybridization experiments gave identical results. 
2.4. Electrophysiology 
cRNA was obtained as previously described [19]. Xenopus oocytes 
(stage V) were manually isolated, followed by a collagenase (Sigma, 
type V) treatment (0.33 mg/ml for 1 h at about 22°C). Oocytes were then 
defolliculated and injected (Drummond Injector) with 23 nl of cRNA 
(approximately 0.014). 1 ¢tg/,ul). For expression, the oocytes were incu- 
bated in modified Barth's solution (88 mM NaC1, 1 mM KC1, 2.4 mM 
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P2X4 MAGC C SV L G S F L F E~D~P RIV L I RSRKV~LMN~AV~qL I A~VIGW~-~VWE ~G~-~ETDSVV- ~VTT~A~VAVTNTSQL GFRIWD~AD~I AQE  N S L F IM~NMIFi~/N~TQST~ 118 
PZXl MARRLQDE LSAFFFE~D~PRMVLVRNKKV~VI F~LIRL~VLV~VIGW~F~YE~G~TSSDLI- ~S~SV~L~LAVTQLQG L PQVWD~AD~F~AHGDSS FVVH~FI~PQ~TQGHRA~[ 119 
P2X2 MVRRLARG CWSA FWD)OE ~IP KVlVVRNRR L~IFVH~IdVRL)- I L L ~FVWY~/F~VQ~S~'OJDS E TG P E B SII IT~qV~G~ITMS E DKVWD . . . . .  ~qE  KvFKpIP EGG SVVS I IF~I EV1]PS~T L GTF.~I 115 
P2X3 MN C I SDF FT~E ~TKSVVVKSWTI r, ll I NB~WDLIL  I S ~FVGW~FIL H E ~AE.~VRDTAI E~_~VVT~V~F RGRYANRVM . . . .  D)~S DE_VIT~PQGTSV FVI I~]KI I~lqE N(~MQG F[JPB l le  
• * * * * * * 
PZX4 IPO- KTSI~N S~AD~TPGSVDTHSS~VA~R~PF- NESVKFE~VAA~V~NOVGVPTPAF LKA~E ~L  LV~N~Y~K~N FSKR~I L PNITTSYL~S~IYNAQTD~F~I FRL~FI ~ 236 
pzx~ NPe--GGz~p~G~PGKAERKAQ~R~Gp~v~F-NG~vK~cE~FG~c~DDKzPsPA~LRE~E~F~LF~N~s~s~?~B<vNRR~-vEEvNG~YM~YHKzQH~FNLp~v ~ z~6 
P2XX SMRVHSST~S~DDF~AGQLDMQGN~IIRTGp~V~YYHGDSKFCE~SA~CP~pGTS-ONHF LGKM~P~F~I L I~N~Yp~FSKG~IASQKSD-YL~[~FOQDSD~Y[~I  FRL~IF I ~ Z33 
P2X3 N E E - - KYR~JVS ~SQ[JG P E RF P - - GG ~I LE~R[J~Y - S SV L R~QG~LE]~TBVOTV -- E MPIMME~dE ~b~_l]1 F I ~S  ER F PIL E~ F E K6 ML L PN LTDKOI ~RERF H P E KA~F ~.eJI L RV~DV~ 223 
. , TM2 , 
PZX4 E OA~HSF~EM~VE ~IM~I Q~K~O~'~RAAS L ~L ~R~S ~RR~DTRD L E H NV~P~Y~YYRD LAG KE Q~T~T~AY~RF~I I ~  I ~ INVG S G LAL L~TV~I  356 
PZX1 RE S~O~RSL~E K~C~VV~T~p~K[ ID~E~HVRH~G~G-- -  EKNL~IP~IF~ FRFA~H FVQ- NGTNR~H~IF~VFpI~F~I L~O~I(~GKFpI~ PT~TTI GSGIGI FpV~TV~C~L L 352 
PXX2 EKAGIENFr~E L~K~C~VI~I~#~[p~ L SE SE[~p~(~S~#~R~ID-- PKYDPA~FRF/~IKYYK INGTTTT~T~AYpI~I~VI~BGKF~ L~ PT~IN LATALTSIpV~SF~C~I 351 
PXX3 KFA~QD~AK L~RT~V L r, II K~JG~VEOL~i(AWDQ[j~ ~K~S EFRI IDGVS E KS SV~P~Y~YYKM E N GS E Y~T~L ~AF~R F ~VL~Y~N~I  ~I  S SVAA FTSV~TV~I  343 
PZX4 V~YCMKKKYY~RDK~YKYVEDYEQGLSGEMNQ 388 
PZXl L~ILPKRHY~QK~FKYAEDMGPGEGEHDPVATSSTLGLQENMRTS 399 
P2X2 L~FMNKNKL~HK~FDKvRTPKHPSSRWPvTLALvLGQ~PPPPSHY~QDQPPSPP~GEGPTLGEGAELPLAvQSPRPCSI~ALTEQvvDTLGQHMGQRPPV~EP~QQDST~TDPKGLA~L472 
P2X3 LL~FLKGADH~KAR~FEEVTETTLKGTASTNPVFASDQATVEKQSTDSGAYSIGH 397 
Fig. 1. Alignment of deduced P2X4 sequence with P2X] [9], P2X2 [10] and P2X 3 [11]. The two putative transmembrane segments are indicated by 
TM1 and TM2 bars. There are eleven conserved cysteines, marked by *. Percent similarity between P2X4 and P2X1, P2X2 or P2X3 is 49%, 43% or 
44%, respectively. The nucleotide sequence of P2X4 has been submitted to the EMBL database under number: X91200. 
NaHCO3, 0.33 mM Ca(NO3)2, 0.82 mM MgSO2, 0.41 mM CaCI2, 15 
mM Tris-Cl, adjusted to pH 7.4 with HC1, supplemented with 50 IU/ml 
penicillin (BRL) and 50/tg/ml streptomycin (BRL)) at 19°C for 3 days 
followed by storage at 4°C until electrophysiological measurements. 
Injected oocytes were analyzed in the two electrode voltage clamp 
configuration (TEC05 amplifier, NPI electronics, Tamm, Germany) 
perfused with NFR (115 mM NaC1, 2.5 mM KC1, 10 mM Hepes 
adjusted to pH 7.2 with HC1 and supplemented with 0.18 mM CaC12 
unless otherwise noted). Data were recorded simultaneously to a chart 
recorder and to a computer hard disk. For chart like digital data 
recording data were typically filtered at 100 Hz, digitized at 300 Hz 
(oversampling) and reduced to 5 Hz before storage. Pulse-like data 
recording was done with synchronous DA and AD conversions at1000 
Hz. Application of perfusion solutions as well as clamp voltage was 
computer controlled. 
2.5. Drugs 
ATP, ADP and AMP (adenosine tri-, di- and mono-phosphate re-
spectively), adenosine, aft-methylene ATP, ATPTS (adenosine 5'-0-(3- 
thio)triphosphate), A4pA (diadenosine t traphosphate), UTP (uridine 
triphosphate) and RB-2 (Reactive Blue 2) were all from Sigma, 2- 
methylthio ATP from Research Biochemicals Intl. (Natick, USA), 
suramin from Bayer AG (Strawberry Hill, Newbury, UK), PPADS 
(pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid) was a gift 
from Prof. G. Lambrecht (University of Frankfurt, Germany). All 
drugs were first made up as a stock solution in water and diluted in 
NFR to the stated concentration. 
3. Results 
3.1. Cloning of the P2X 4 purinoceptor 
Low stringency library screening identified cDNA clones 
whose deduced amino sequence are clearly, but distantly re- 
lated to the P2X1 and P2X2 sequences. The deduced amino acid 
(Fig. 1) predicts a protein of 43.5 kDa which is about equidis- 
tantly related to the three other known P2X sequences. The 
P2X4 sequence has the two putative transmembrane s gments 
and the 11 conserved cysteine residues considered characteristic 
for this gene family. 
3.2. Tissue distribution of expression 
P2X4 was isolated from a hippocampal rat brain cDNA li- 
brary. High specific RNA levels were detected in cerebellar 
Purkinje cells and spinal cord motor neurons (Fig. 3) and me- 
dulla oblongata (not shown). Weaker in situ hybridization sig- 
nals were detected in the hippocampus and olfactory bulb (not 
shown). The medial habenula revealed no detectable P2X4 hy- 
bridization signal in our experiments. 
Northern blotting revealed widespread expression of P2X4 
A + RNA of a length of 1.9 kb. All of the tested tissues revealed 
comparable amounts of specific mRNA. With the exception of 
RNA isolated from testis, only a single RNA species was de- 
tected. 
3.3. Recombinant expression 
Xenopus oocytes injected with P2X4 RNA yielded consis- 
tently robust instant currents after ATP application. Even at 
Fig. 2. Expression of P2X 4 specific mRNA detected by Northern blot. 
3.2/zg of A + RNA was loaded per lane, except for RNA from bladder 
(1.6/tg). No signal was detected on 3.2/zg of brain total RNA (not 
shown). 
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Fig. 3. P2X 4 Dig probes label individual Purkinje cells in cerebellar 
cortex (A) and motor neurons in spinal cord (B). (A) is a coronal 
section; scale bar: 500/~m. (B) is a transversal section of the lumbar 
spinal cord; scale bar = 1000/tm. 
low ATP concentrations, responses howed partial desensitiza- 
tion. P2X4 purinoceptors showed prolonged periods necessary 
for recovery from desensitization. We found that wash periods 
of 10-15 min were necessary to allow for full recovery (data not 
shown). This slow recovery seriously hampered experiments. 
All other compounds that acted as agonists (Table 1) showed 
this kinetic pattern. We tested whether the ATP evoked re- 
sponse is abolished by unrecovered desensitization from previ- 
ously applied ~,fl-MeATP. We found that pre-application of 
100 pM ~,fl-MeATP for 3 min resulted in a reduced ATP 
Table 1 
Agonist potency ratios 
Compound (n = 4) Relative potency ratio 
ATP 1 
ATPTS 0.435 + 0.046 
2-Methylthio ATP 0.136 + 0.016 
ADP 0.036 + 0.003 
aft-Methylene ATP 0.030 + 0.002 
AMP No response 
Adenosine No response 
UTP No response 
Diadenosine tetraphosphate No response 
No response: voked currents < 10 nA with compounds tested up to 300 
pM. 
evoked response (still > 50% of control with 3 / tM ATP), but 
not in a complete suppression (data not shown). 
We found further that the observed esensitization was iden- 
tical under low, 180 #M,  Ca 2+ concentration (Fig. 4a) or Ca 2+ 
substitution by 1800 #M Ba 2+ (not shown) in the perfusion 
solution. These conditions should have minimized artifacts 
through Ca z+ activated chloride channels. P2X 4 channels dis- 
played an identical inward rectification in low Ca 2÷ or standard 
Ba 2÷ conditions (Fig, 4b). We did not attempt to determine 
permeability of the P2X4 channel for Ca 2+ ions. 
The apparent concentration for half maximal response 
(ECs0) was 10/.tM for ATP (n = 4) using the initial peak re- 
sponse after agonist application (Fig 5). The precision of this 
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Fig. 4. (A) ATP-evoked currents in Xenopus oocytes injected with P2X 4 
cRNA. 10,uM ATP was applied to oocytes perfused with NFR contain- 
ing 180/~M Ca 2+. Same time course of current response was obtained 
when NFR contained 1800/IM Ba :÷ (not shown). Holding potential 
-60 mV. No ATP evoked responses were detected inuninjected oocytes 
(n > 5) or oocytes injected with NMDA receptor cRNA. (B) I-Vcurves 
of P2X4 receptors obtained through voltage ramps. Voltage ramps were 
applied during the plateau phase of the agonist (3 ~tM ATP) response. 
Leakage current was subtracted. Leakage current was determined from 
an identical ramp just before agonist application. Only the ramp seg- 
ment from +5 mV to -105 mV, duration 1 s, is displayed, cRNA 
injection was adjusted to yield lower macroscopic currents in (A) than 
in (B) 
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Fig. 5. Dose-response curve for ATP. The initial peak value of the 
current response was used. n = 4. 
value is limited in view of the significant desensitization at
higher ATP concentration, the fact that the maximal response 
could not be clearly determined and the relative slow solution 
exchange rates inherent o oocyte whole cell configurations. 
Several ATP-related substances activated P2X 4 channels. We 
determined the following rank order of potency: 
ATP > ATPTS > 2-MeSATP > ADP -- afl-MeATP at low con- 
centrations (Table 1). At high concentration both 300 BM ADP 
and 100 pM afl-MeATP were less efficacious than ATE Other 
compounds used to discriminate purinoceptors such as UTP, 
AMP, adenosine and A4pA did not evoke any measurable 
response at high or low concentrations (Table 1). 
We further tested commonly used purinoceptor antagonists 
on recombinant P2X 4 purinoceptors. Neither PPADS, which 
is considered selective for P2X purinoceptors, nor the non- 
specific P2-purinoceptor antagonist suramin nor RB-2 antago- 
nized (all tested up to 50 ~tM) ATP evoked responses (Fig. 6); 
nor did they act as agonists. Prolonged pre-application (up to 
15 min) of those compounds still did not reveal any antagonistic 
effect (not shown). On the contrary, all the P2X 'antagonists' 
used showed some potentiation of ATP evoked responses (Fig. 
6). 
4. Discussion 
We propose to call the newly identified purinoceptor P2X 4 
following the proposed nomenclature for P2X purinoceptor 
subunits [20]. P2X4 is about equidistantly related to P2X 1, P2X2 
and P2X3 and is not a closely related family member to any 
those subunits. 
The deduced P2X sequence would predict he expected two 
membrane spanning topology, with both, the C and N termini 
located intracellularly. Remarkably all cysteines located within 
the proposed extracellular domain are conserved throughout 
the P2X family, suggesting a role for maintaining the tertiary 
structure of the mature protein. 
P2X 4 is the first P2X subunit hat is highly expressed in the 
CNS, specifically in the cerebellum and the spinal cord. Lower 
expression levels have been detected in the hippocampus. Radi- 
oligand binding studies [21] and autoradiography [15] using 
~zfl-methylene ATP have suggested the presence of P2X recep- 
tors in the brain and spinal cord. P2X 4 expression pattern 
overlaps with ~fl-MeATP labeling, but there are areas like the 
thalamus which are strongly marked by efl-MeATP but do not 
reveal P2X4 RNA expression. These data suggest that there is 
an additional, as yet unidentified P2X subtype in the brain. 
ATP mediated fast synaptic transmission i the medial habe- 
nula can be blocked by suramin [22]. P2X4 message was not 
detected in this brain area and recombinant P2X4 are not 
blocked by suramin. 
The lack of blockade of P2X 4 receptors by suramin, PPADS 
and RB-2 was totally unexpected. All these compounds block 
recombinant P2XI 3, where tested [8,9,10,11]. Those com- 
pounds have been widely used to discriminate P2 receptors 
[23,24]. We found that suramin, PPADS and RB-2 all potenti- 
ate ATP evoked recombinant P2X 4 responses at least when 
expressed in Xenopus oocytes. It would be intriguing to specu- 
late whether the facilitation of hippocampal potentials by 
suramin described by Wieraszko [25] are mediated through 
suramin potentiation of P2X4 receptors. 
The newly cloned P2X4 receptor has the rank order of po- 
tency of ATP > ATPT/S > 2-MeSATP >> c~,fl-MeATP = ADP, 
which is different from the other cloned P2X receptors for 
which 2-MeSATP and ATP are the two most potent agonists. 
The low potency of ~,fl-MeATP might explain the weak cross 
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Fig. 6. Effects of PPADS, suramin and RB-2 on ATP evoked responses 
in oocytes expressing P2X 4 receptors. Wash period between ATP pre- 
application and ATP + substance test application was 10 min, 2nd 
wash period was 20 min. ATP was 3/tM, other substances 50/2M. All 
displayed data are from one single oocyte. Total duration of experiment 
was 3 h. Holding potential -60 mV. No leakage current subtraction was 
performed. The instability of measured current seen in (C) after RB-2 
application was seen consistently. In control experiment on recombi- 
nant P2Xz purinoceptors these compounds acted as published as antag- 
onists (not shown). 
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desensitiztion caused by this compound, c~,fl-MeATP cross de- 
sensitization has been used to discriminate P2X-type of re- 
sponses from other purinoceptor mediated [5]. This approach 
does not appear to be useful for identifying purinoceptors of 
the P2X4 subtype. 
Ueno et al. [26] described an ATP gated current in primary 
neuronal cultures of rat nucleus solitarii with a rank order of 
agonists imilar to the one we determined for the P2X 4 type. 
Outside of the CNS, purinoceptor mediated responses have 
been detected with a profile of agonist potency similar to that 
of P2X 4 [27]. P2X 4 message was found to be widely expressed 
throughout many different issues; thus the P2X4 subtype ap- 
pears to be the most widespread member of the P2X family. 
This is strikingly in contrast o the very restricted expression 
of the P2X 3 RNA. Particularly interesting is the co-expression 
of P2X1 and P2X4 in vas deferens which could give raise to 
heteromeric ATP purinoceptors. Whereas the presence of P2X 
purinoceptors in lung, vas deferens and bladder has been gener- 
ally accepted after numerous pharmacological experiments, the 
evidence for presence of purinoceptors of the P2X type in testis, 
thymus and adrenals was more tentative. We have now found 
P2X4 message in all these tissues. A fast ATP evoked response 
[27] with an agonist potency profile already discussed above 
and that was potentiated by RB-2 has been described in guinea- 
pig intracardiac neurons which the authors tentatively classi- 
fied as a P2Y-type response. However, in view of our P2X 4 
data, it is quite likely that this response was mediated by a 
P2Xn-type of purinoceptor. Barajas-Lopez et al. [28] found an 
ATP activated current in myenteric neurons that is potentiated 
by suramin and therefore might well be mediated through the 
P2X4 type. 
We have described a new P2X purinoceptors subtype cDNA 
which confers a novel and unique pharmacology. This type of 
pharmacology was unexpected and suggests that some of the 
previously uninterpretable data can now be classified as genu- 
ine P2X purinoceptor mediated events. The current lack of any 
P2X 4 antagonist makes the full evaluation of the significance 
of the P2X4 purinoceptor subtype difficult. However, the clon- 
ing of the P2X 4 cDNA will be helpful in developing the neces- 
sary tools. The widespread P2X4 mRNA expression reinforces 
the view that P2X receptors are involved in a large number of 
physiological processes. 
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